LSV Asset Management Sells 207,400 Shares of Lantheus Holdings, Inc. $LNTH

LSV Asset Management reduced its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 73.1% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 76,400 shares of the medical equipment provider’s stock after selling 207,400 shares during the quarter. LSV Asset Management’s holdings in Lantheus were worth $3,919,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the business. Hantz Financial Services Inc. lifted its stake in shares of Lantheus by 412.5% in the 3rd quarter. Hantz Financial Services Inc. now owns 492 shares of the medical equipment provider’s stock valued at $25,000 after purchasing an additional 396 shares during the period. Elevation Point Wealth Partners LLC bought a new stake in Lantheus in the second quarter valued at about $26,000. First Horizon Corp bought a new stake in Lantheus in the third quarter valued at about $26,000. Osterweis Capital Management Inc. acquired a new position in Lantheus in the second quarter valued at about $36,000. Finally, Pilgrim Partners Asia Pte Ltd bought a new position in Lantheus during the third quarter worth about $59,000. Institutional investors and hedge funds own 99.06% of the company’s stock.

Lantheus Price Performance

Shares of LNTH opened at $69.38 on Monday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 2.49 and a current ratio of 2.67. The stock has a 50 day simple moving average of $66.30 and a 200 day simple moving average of $59.38. Lantheus Holdings, Inc. has a 52-week low of $47.25 and a 52-week high of $111.29. The firm has a market capitalization of $4.60 billion, a PE ratio of 29.15 and a beta of -0.08.

Analysts Set New Price Targets

Several research firms have recently issued reports on LNTH. Mizuho boosted their target price on Lantheus from $60.00 to $72.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 17th. Truist Financial lifted their price objective on shares of Lantheus from $80.00 to $82.00 and gave the stock a “buy” rating in a research note on Thursday, December 18th. Finally, Weiss Ratings raised shares of Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, January 6th. Five investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, Lantheus has a consensus rating of “Moderate Buy” and a consensus price target of $78.00.

Lantheus Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.